MNKD · Mannkind Corp
$3.91
-0.04 (-1.01%)
At close · Jul 28
Market Cap
$1.21B
Shares
308.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.91
Open$3.95
Day$3.84–4.00
52W$2.23–6.51
Avg vol 30d5.0M
Short int28.2M · 9.1% float · 5.9d
Short vol54%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+3%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
39%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−37%
trailing
YTD return
−31%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
56 of 253 funds reported for Jun 30 · net +418.9K sh shares · +11 new
Insider flow
Distributing
Net -$65.7K over 90 days · 100% sells
Short interest
Rising
9.12% of float · ▲ +7.7% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+22%
Y/Y
EPS growth
−80%
Y/Y
Free cash flow
$13.7M
Balance sheet
$44.0M
net debt
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
FURO6 revenue
· full-year 2026
Initiated
$110M – $120M
prior FY $348.97M
midpoint −67.0% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+3%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
39%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
56 of 253 funds reported for Jun 30 · net +418.9K sh shares · +11 new
Insider flow
Distributing
Net -$65.7K over 90 days · 100% sells
Short interest
Rising
9.12% of float · ▲ +7.7% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 39%
52-wk high $7
vs 200-day avg -10%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| doses dispensed increase | 64% | first quarter of 2026 | — |
| Non-GAAP adjusted net income (loss) non-GAAP | $59,516K | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNKD
this stock
Mannkind Corp
|
$1.21B | -31.0% | +22.2% | — | 9.1% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNKD | -3.5% | -4.5% | -37.0% | -8.2% | -31.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.5% | -4.5% | -44.5% | -7.4% | -39.7% |
Key facts
CIK
899460
CUSIP
56400P706
13F (30d)
49 filings
49 filers
Visit website
Investor relations